Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases ...

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...

Conflicting findings in environmental epidemiology have long stalled consensus on the health effects of toxic chemicals. A new study by Columbia University Mailman School of Public Health published in ...

The five medical centers overseen by the University of California have collected more than a decade's worth of surgical data, allowing it to streamline care and improve financial margins, which has ...

Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 ...

Conflicting findings in environmental epidemiology have long stalled consensus on the health effects of toxic chemicals. A new study suggests that one major reason for these inconsistencies may be the ...